2 Mar 2010

UCB: Solid foundation for sustainable growth

Read More
29 Jan 2010

UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.

Read More
21 Dec 2009

UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn's disease

Read More
15 Dec 2009

UCB signs a new EUR 1.5 billion credit facility

Read More
3 Dec 2009

UCB completes the placement of 7-year bonds

Read More
3 Dec 2009

UCB launches offering of 7-year bonds

Read More
10 Nov 2009

Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)

Read More
6 Nov 2009

UCB Extraordinary General Meeting

Read More
27 Oct 2009

UCB successfully completes its fixed rate bonds - Early termination of the offer period - Total amount is set at EUR 750 million

Read More
23 Oct 2009

UCB to offer a minimum of EUR 150 million[1] in 5-year fixed rate bonds

Read More
Subscribe to